Delirium: pre-publication check
Following consultation on the provisional recommendations, the National Clinical Guideline Centre for Acute and Chronic Conditions and the Delirium Guideline Development Group (GDG) have considered and responded to stakeholder comments and amended the draft guideline.
The revised full guideline is now available on the web for a pre-publication check of factual errors. Factual errors are instances where there is an objective error of material fact in the guideline. They do not include disagreement about scientific or clinical interpretation or judgement, because this cannot be defined as an objective error of material fact.
This is still draft guidance and has not been sent out to the NHS. The pre-publication check is not a second consultation or an opportunity to reopen arguments and issue highlighted during consultation on the draft guidelines. The GDG will already have considered these issues in forming the recommendations contained in the draft for the pre-publication check.
Registered stakeholders for this guideline are invited to report any factual errors in the guideline via this website.
Pre-publication check dates: 17 May -7 June 2010
Pre-publication check documents
- Full guideline
- Full guideline appendices
- Consultation table and with developers responses
- Pre-publication form
Please use the report form to notify any errors and return by email to delirium@nice.org.uk
The Institute is unable to accept:
- More than one form per stakeholder organisation
- Forms received after the deadline (5pm on 7 June 2010)
- Comments that are not on the correct form
- Confidential information or other material that you would not wish to be made public
- Personal medical information about yourself or another person from which your or the person’s identity could be ascertained.
What will happen to your response:
- After the closing date, the NCC, GDG and NICE will meet to consider the stakeholders’ responses. If any corrections are necessary, the developers will revise the full guideline and resubmit to NICE.
- All reports of factual errors and responses will be published on the NICE website with the final guideline.
- No action will be taken upon receipt of personal, individual comments and late comments.
Please note:
The pre-publication check will take place before editing of the recommendations is finished. Therefore there may be changes in some recommendations in the final published version, for reasons other than factual accuracy.
Acknowledgement
You should receive an automated acknowledgement from the email box when you email your report form. If you do not receive this acknowledgement, please contact the relevant Guidelines Coordinator to ensure your comments have been safely received.
Anticipated publication date: tbc
Further information
This page was last updated: 23 July 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Appendix D diagnostic test accuracy - included studies (PDF 182 KB)
-
-
Appendix D non pharmacological risk factors - included studies (PDF 90 KB)
-
Appendix D pharmacological risk factors - included studies (PDF 49 KB)
-
Appendix E consequences of cohort studies - methodological quality (PDF 125 KB)
-
Appendix E diagnostic accuracy tests - methodological quality (PDF 172 KB)
-
Appendix E epidemiology - methodological quality (PDF 168 KB)
-
Appendix E non-pharmacological risk factors cohort studies - methodological quality (PDF 44 KB)
-
Appendix E pharmacological risk factors cohort studies - methodological quality (PDF 29 KB)
-
Appendix E patient information - methodological quality (PDF 213 KB)
-
Appendix F consequences of - multivariate risk factors (PDF 185 KB)
-
Appendix F - non-pharmacological risk factors - multivariate risk factors (PDF 293 KB)
-
Appendix F pharmacological risk factors - multivariate risk factors (PDF 63 KB)
-
Appendix G diagnostic test accuracy - excluded studies (PDF 128 KB)
-
Appendix G adverse effects review - excluded studies (PDF 121 KB)
-
-
Appendix G epidemiology review - excluded studies (PDF 146 KB)
-
Appendix G non-pharmacological risk factors - excluded studies (PDF 71 KB)
-
Appendix G information for patients review - excluded studies (PDF 118 KB)
-
Appendix G pharmacological risk factors - excluded studies (PDF 55 KB)
-
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)
-
Pre-publication check - stakeholder comments/developer responses (PDF 49 KB)
-
-
-
-
-
Appendix D - Adverse Effects - Included studies (PDF 121 KB)
-
Appendix D - Consequences of - Included studies (PDF 155 KB)
-
Appendix D - Diagnostic Test Accuracy - Included Studies (PDF 182 KB)
-
-
Appendix D - Non pharmacological Risk factor - Included studies (PDF 44 KB)
-
Appendix D - Pharma Nonpharma Prevention Treatment - Included studies (PDF 170 KB)
-
Appendix D - Pharmacological Risk factors - Included studies (PDF 49 KB)
-
-
Appendix E - Diagnostic Accuracy Tests Methodological Quality (PDF 172 KB)
-
-
-
-
Appendix E - Pharma NonPharma Prevention Treatment (PDF 107 KB)
-
Appendix E - Pharmacological Risk Factors review - Randomised controlled trials (PDF 23 KB)
-
Appendix E - Pharmacological Risk Factors review - cohort studies (PDF 30 KB)
-
-
Appendix H - Recommendations for Future Research (PDF 75 KB)
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)